Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The induction of broadly neutralizing antibodies (bNAbs) is a potential strategy for a vaccine against HIV-1. However, most bNAbs exhibit features such as unusually high somatic hypermutation, including insertions and deletions, which make their induction challenging. VRC01-class bNAbs not only exhibit extraordinary breadth and potency but also rank among the most highly somatically mutated bNAbs. Here, we describe a VRC01-class antibody isolated from a viremic controller, BG24, that is much less mutated than most relatives of its class while achieving comparable breadth and potency. A 3.8-Å x-ray crystal structure of a BG24-BG505 Env trimer complex revealed conserved contacts at the gp120 interface characteristic of the VRC01-class Abs, despite lacking common CDR3 sequence motifs. The existence of moderately mutated CD4-binding site (CD4bs) bNAbs such as BG24 provides a simpler blueprint for CD4bs antibody induction by a vaccine, raising the prospect that such an induction might be feasible with a germline-targeting approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374330PMC
http://dx.doi.org/10.1126/sciadv.abp8155DOI Listing

Publication Analysis

Top Keywords

cd4-binding site
8
bnabs exhibit
8
breadth potency
8
bnabs
5
naturally arising
4
arising broad
4
broad potent
4
potent cd4-binding
4
site antibody
4
antibody low
4

Similar Publications

Digital reconstruction of full embryos during early mouse organogenesis.

Cell

August 2025

Department of Cardiac Surgery, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, Key Laboratory of Developmental Genes and Human Disease, State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, School of Life Science and

Early organogenesis is a crucial stage in embryonic development, characterized by extensive cell fate specification to initiate organ formation but also by a high susceptibility to developmental defects. Here, we profiled 285 serial sections from six E7.5-E8.

View Article and Find Full Text PDF

HIV-1-mediated CD4 downregulation is a well-known mechanism that protects infected cells from antibody-dependent cellular cytotoxicity (ADCC). While CD4 downregulation by HIV-1 Nef and Vpu proteins has been extensively studied, the contribution of the HIV-1 envelope glycoprotein (Env) in this mechanism is less understood. While Env is known to retain CD4 in the endoplasmic reticulum (ER) through its CD4-binding site (CD4bs), little is known about the mechanisms underlying this process.

View Article and Find Full Text PDF

Administration of HIV-1 neutralizing antibodies can suppress viremia and prevent infection . However, clinical use is challenged by broad envelope sequence diversity and rapid emergence of viral escape . Here, we performed single B cell profiling of 32 top HIV-1 elite neutralizers to identify broadly neutralizing antibodies (bNAbs) with highest potency and breadth for clinical application.

View Article and Find Full Text PDF

Background: VH3810109 (N6LS) is a CD4-binding site antibody with broad and potent neutralizing activity in vitro. Here, we present efficacy, safety, and pharmacokinetic results from the phase 2a BANNER study in people with HIV-1.

Methods: BANNER was a randomized, open-label, 2-part, multicenter study of N6LS in adults naive to antiretroviral therapy (ART) with HIV-1 RNA ≥5000 copies/mL.

View Article and Find Full Text PDF

The development of an effective vaccine against HIV-1 requires understanding how broadly neutralizing antibodies (bNAbs) evolve in natural viral infections. Here, we recovered 152 envelope sequences from two elite neutralizers (ENs) and five viral controllers and determined the neutralization sensitivity (IC) of each envelope glycoprotein (Env) to broadly neutralizing monoclonal antibodies (bN-mAbs). For the combined EN/controller data set, we observed that the median IC value for a CD4-binding site (CD4bs) bN-mAb (VRC01) was significantly lower for viruses lacking an N465 glycan.

View Article and Find Full Text PDF